AC
HZNP

Ascend Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ascend Capital’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-220,000
Closed -$3.33M – 227
2014
Q1 		$3.33M Sell
220,000
-110,000
-33% -$1.24M 0.09% 159
2013
Q4 		$2.52M Buy
+330,000
New +$1.78M 0.08% 161

Other funds holding HZNP

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Ascend Capital's HZNP Position: Q2 2014 in Review

Ascend Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2014, closing a stake of 220,000 shares — an estimated $3.33M sold.

Ascend Capital first reported a position in HZNP in Q4 2013 and held it in 2 quarters. The position peaked at $3.33M in Q1 2014. 141 funds tracked by Wall St. Rank hold HZNP as of Q2 2014.

  • Ascend Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2014 after selling out during the quarter.
  • Ascend Capital sold 220,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2014, an estimated $3.33M.
  • Ascend Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 2 quarters.
  • Ascend Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.33M in Q1 2014.
  • 141 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2014.

Based on Ascend Capital's 13F filing for Q2 2014, filed 13 Aug 2014.